Skip to main content
PMC home page
Clinical Cardiology logoLink to Clinical Cardiology
. 2006 Dec 5;25(10):447–454. doi: 10.1002/clc.4960251003

Anticoagulants for atrial fibrillation: Why is the treatment rate so low?

Thomas A Buckingham 1,✉, Robert Hatala 2
PMCID: PMC6654570  PMID: 12375802

Abstract

The incidence of atrial fibrillation (AF) is increasing in many countries along with aging demographics. Atrial fibrillation is clearly associated with an increased rate of stroke. Numerous large clinical trials have shown that dose‐adjusted warfarin can reduce the stroke rate in these patients, particularly in the elderly, and clear guidelines for the use of anticoagulants in such patients have been published. However, many studies show that treatment rates remain disappointingly low (≤50%). Numerous barriers to the use of dose‐adjusted warfarin exist, including practical, patient‐, physician‐, and healthcare system‐related barriers. These include the complex pharmacokinetics of warfarin, the need for continuous prothrombin time monitoring and dose adjustments, bleeding events, noncompliance, drug interactions, and increased costs of monitoring and therapy. Possible solutions to this problem are discussed and include improved patient and physician education, the use of anticoagulation clinics, new approaches to AF, and potential treatment improvements through use of newer anticoagulants.

Keywords: atrial fibrillation, anticoagulation, compliance rates, stroke prevention, underutilization

Full Text

The Full Text of this article is available as a PDF (54.7 KB).

References

  • 1. Wolf PA, Abbott RD, Kannel WB: Atrial fibrillation as an independent risk factor for stroke: The Framingham Study. Stroke 1991; 22: 983–988 [DOI] [PubMed] [Google Scholar]
  • 2. Connolly SJ, Laupacis A, Gent M, Roberts RS, Cairns JA, Joyner C: Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. J Am Coll Cardiol 1991; 18: 349–355 [DOI] [PubMed] [Google Scholar]
  • 3. EAFT (European Atrial Fibrillation Trial) Study Group : Secondary prevention in non‐rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993; 342: 1255–1262 [PubMed] [Google Scholar]
  • 4. Ezekowitz MD, Bridgers SL, James KE, Carliner NH, Colling CL, Gornick CC, Krause‐Steinrauf H, Kurtzke JF, Nazarian SM, Radford MJ, Riclkel FR, Shabetai R, Deykin D, for the Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators : Warfarin in the prevention of stroke associated with non‐rheumatic atrial fibrillation. N Engl J Med 1992; 327: 1406–1412 [DOI] [PubMed] [Google Scholar]
  • 5. Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B: Placebo‐controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Lancet 1989; 1: 175–179 [DOI] [PubMed] [Google Scholar]
  • 6. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators : The effect of low‐dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med 1990; 323: 1505–1511 [DOI] [PubMed] [Google Scholar]
  • 7. Stroke Prevention in Atrial Fibrillation Study . Final results. Circulation 1991; 84: 527–539 [DOI] [PubMed] [Google Scholar]
  • 8. Feinberg WM, Blackshear JL, Laupacis A, Kronmal R, Hart RG: Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications. Arch Intern Med 1995; 155: 469–473 [PubMed] [Google Scholar]
  • 9. Gustafsson C, Blomback M, Britton M, Hamsten A, Svensson J: Coagulation factors and the increased risk of stroke in nonvalvular atrial fibrillation. Stroke 1990; 21: 47–51 [DOI] [PubMed] [Google Scholar]
  • 10. Seidl K, Hauer B, Schwick NG, Zellner D, Zahn R, Senges J: Risk of thromboembolic events in patients with atrial flutter. Am J Cardiol 1998; 82: 580–583 [DOI] [PubMed] [Google Scholar]
  • 11. The Atrial Fibrillation Investigators : Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994; 154: 1449–1457 [PubMed] [Google Scholar]
  • 12. Stroke Prevention in Atrial Fibrillation III randomised clinical trial : Adjusted‐dose warfarin versus low‐intensity, fixed‐dose warfarin plus aspirin for high‐risk patients with atrial fibrillation. Lancet 1996; 348: 633–638 [PubMed] [Google Scholar]
  • 13. Hart RG, Benavente O, Pearce LA: Increased risk of intracranial hemorrhage when aspirin is combined with warfarin: A meta‐analysis and hypothesis. Cerebrovasc Dis 1999; 9: 215–217 [DOI] [PubMed] [Google Scholar]
  • 14. Bar‐Sela S, Ehrenfeld M, Eliakim M: Arterial embolism in thyrotoxicosis with atrial fibrillation. Arch Intern Med 1981; 141: 1191–1192 [PubMed] [Google Scholar]
  • 15. The Stroke Prevention in Atrial Fibrillation Investigators Committee on Echocardiography : Transesophageal echocardiographic correlates of thromboembolism in high‐risk patients with nonvalvular atrial fibrillation. Ann Intern Med 1998; 128: 639–647 [DOI] [PubMed] [Google Scholar]
  • 16. Prystowsky EN, Benson DW Jr, Fuster V, Hart RG, Kay GN, Myerburg RJ, Naccarelli GV, Wyse DG: Management of patients with atrial fibrillation. A Statement for Healthcare Professionals. From the Subcommittee on Electrocardiography and Electrophysiology, American Heart Association. Circulation 1996; 93: 1262–1277 [DOI] [PubMed] [Google Scholar]
  • 17. Albers GW, Dalen JE, Laupacis A, Manning WJ, Petersen P, Singer DE: Antithrombotic therapy in atrial fibrillation. Chest 2001; 119: 194S–206S [DOI] [PubMed] [Google Scholar]
  • 18. Fuster V, Ryden LE, Asinger RW, Cannom DS, Crijns HJ, Frye RL, Halperin JL, Kay GN, Klein WW, Levy S, McNamara RL, Prystowsky EN, Wann LS, Wyse DG, Gibbons RJ, Antman EM, Alpert JS, Faxon D: ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: Executive summary‐a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee. Circulation 2001; 104: 2118–2150 [PubMed] [Google Scholar]
  • 19. Adhiyaman V, Kamalakannan D, Oke A, Shah IU, White AD: Underutilization of antithrombotic therapy in atrial fibrillation. J R Soc Med 2000; 93: 138–140 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20. Flaker GC, McGowan DJ, Boechler M, Fortune G, Gage B: Underutilization of antithrombotic therapy in elderly rural patients with atrial fibrillation. Am Heart J 1999; 137: 307–312 [DOI] [PubMed] [Google Scholar]
  • 21. Mendelson G, Aronow WS: Underutilization of warfarin in older persons with chronic nonvalvular atrial fibrillation at high risk for developing stroke. J Am Geriatr Soc 1998; 46: 1423–1424 [DOI] [PubMed] [Google Scholar]
  • 22. Carlsson J, Dees G, Miketic E, Sorges SSH, Cuneo A: Stroke prevention practices in patients with atrial fibrillation and pacemaker therapy: Evidence for underutilization of anticoagulation. Eur Heart J 1999; 20: 224–224 [DOI] [PubMed] [Google Scholar]
  • 23. Sweeney KG, Gray DP, Steele R, Evans P: Use of warfarin in non‐rheumatic atrial fibrillation: A commentary from general practice. Br J Gen Pract 1995; 45: 153–158 [PMC free article] [PubMed] [Google Scholar]
  • 24. Denham MJ, Barnett NL: Drug therapy and the older person: Role of the pharmacist. Drug Saf 1998; 19: 243–250 [DOI] [PubMed] [Google Scholar]
  • 25. Bungard TJ, Ghali WA, Teo KK, McAlister FA, Tsuyuki RT: Why do patients with atrial fibrillation not receive warfarin? Arch Intern Med 2000; 160: 41–46 [DOI] [PubMed] [Google Scholar]
  • 26. Beyth RJ, Antani MR, Covinsky KE, Miller DG, Chren MM, Quinn LM, Landefeld CS: Why isn't warfarin prescribed to patients with nonrheumatic atrial fibrillation? J Gen Intern Med 1996; 11: 721–728 [DOI] [PubMed] [Google Scholar]
  • 27. Brodsky MA, Chun JG, Podrid PJ, Douban S, Allen BJ, Cygan R: Regional attitudes of generalists, specialists, and subspecialists about management of atrial fibrillation. Arch Intern Med 1996; 156: 2553–2562 [PubMed] [Google Scholar]
  • 28. Chang HJ, Bell JR, Deroo DB, Kirk JW, Wasson JH: Physician variation in anticoagulating patients with atrial fibrillation. Dartmouth Primary Care COOP Project. Arch Intern Med 1990; 150: 83–86 [PubMed] [Google Scholar]
  • 29. Kutner M, Nixon G, Silverstone F: Physicians' attitudes toward oral anticoagulants and antiplatelet agents for stroke prevention in elderly patients with atrial fibrillation. Arch Intern Med 1991; 151: 1950–1953 [PubMed] [Google Scholar]
  • 30. Lip GY, Zarifis J, Watson RD, Beevers DG: Physician variation in the management of patients with atrial fibrillation. Heart 1996; 75: 200–205 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31. McCrory DC, Matchar DB, Samsa G, Sanders LL, Pritchett EL: Physician attitudes about anticoagulation for nonvalvular atrial fibrillation in the elderly. Arch Intern Med 1995; 155: 277–281 [PubMed] [Google Scholar]
  • 32. Monette J, Gurwitz JH, Rochon PA, Avorn J: Physician attitudes concerning warfarin for stroke prevention in atrial fibrillation: Results of a survey of long‐term care practitioners. J Am Geriatr Soc 1997; 45: 1060–1065 [DOI] [PubMed] [Google Scholar]
  • 33. Rodgers H, Sudlow M, Dobson R, Kenny RA, Thomson RG: Warfarin anticoagulation in primary care: A regional survey of present practice and clinicians' views. Br J Gen Pract 1997; 47: 309–310 [PMC free article] [PubMed] [Google Scholar]
  • 34. Callegari S, Pini M, Andreoli L: Guidelines and clinical practice: Anticoagulant therapy and cardioversion in atrial fibrillation. G Ital Cardiol 1999; 29: 1157–1163 [PubMed] [Google Scholar]
  • 35. Gottlieb LK, Salem‐Schatz S: Anticoagulation in atrial fibrillation. Does efficacy in clinical trials translate into effectiveness in practice? Arch Intern Med 1994; 154: 1945–1953 [DOI] [PubMed] [Google Scholar]
  • 36. Taylor F, Ramsay M, Voke J, Cohen H: Anticoagulation in patients with atrial fibrillation. GPs not prepared for monitoring anticoagulation (letter). Br Med J 1993; 307: 1493 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37. Pubentz MJ, Calcagno DE Jr, Teeters JL: Improving warfarin anti‐coagulation therapy in a community health system. Pharm Pract Manag Q 1998; 18: 1–16 [PubMed] [Google Scholar]
  • 38. Man‐Son‐Hing M, Laupacis A, O'Connor A, Wells G, Lemelin J, Wood W, Dermer M: Warfarin for atrial fibrillation. The patient's perspective. Arch Intern Med 1996; 156: 1841–1848 [PubMed] [Google Scholar]
  • 39. Fareed J, Lewis B, Callas D, Hoppensteadt D, Walenga J, Bick R: Antithrombin agents: The new class of anticoagulant and anti‐thrombotic drugs. Clin Appl Thromb Hemost 2000;(suppl 1): S45–S55 [DOI] [PubMed]
  • 40. Olsson SB, Petersen P: Fixed‐dose oral direct thrombin inhibitor ximelagatran as an alternative for dose‐adjusted warfarin in patients with non‐valvular atrial fibrillation. Eur Heart J 2001; 22: 330 [Google Scholar]
  • 41. Albers GW, Bittar N, Young L, Hattemer CR, Gandhi AJ, Kemp SM, Hall EA, Morton DJ, Yim J, Vlasses PH: Clinical characteristics and management of acute stroke in patients with atrial fibrillation admitted to US university hospitals. Neurology 1997; 48: 1598–1604 [DOI] [PubMed] [Google Scholar]
  • 42. Antani MR, Beyth RJ, Covinsky KE, Anderson PA, Miller DG, Cebul RD, Quinn LM, Landefeld CS: Failure to prescribe warfarin to patients with nonrheumatic atrial fibrillation. J Gen Intern Med 1996; 11: 713–720 [DOI] [PubMed] [Google Scholar]
  • 43. Bath PM, Prasad A, Brown MM, MacGregor GA: Survey of use of anticoagulation in patients with atrial fibrillation (letter). Br Med J 1993; 307: 1045 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44. Brass LM, Krumholz HM, Scinto JM, Radford M: Warfarin use among patients with atrial fibrillation. Stroke 1997; 28: 2382–2389 [DOI] [PubMed] [Google Scholar]
  • 45. The Clinical Quality Improvement Network (CQIN) Investigators : Thromboembolic prophylaxis in 3575 hospitalized patients with atrial fibrillation. Can J Cardiol 1998; 14: 695–702 [PubMed] [Google Scholar]
  • 46. Gage BF, Boechler M, Doggette AL, Fortune G, Flaker GC, Rich MW, Radford MJ: Adverse outcomes and predictors of underuse of antithrombotic therapy in medicare beneficiaries with chronic atrial fibrillation. Stroke 2000; 31: 822–827 [DOI] [PubMed] [Google Scholar]
  • 47. Gaughan GL, Dolan C, Wilk‐Rivard E, Geary G, Libbey R, Gilman MA, Lanata H: Improving management of atrial fibrillation and anticoagulation in a community hospital. Jt Comm J Qual Improv 2000; 26: 18–28 [DOI] [PubMed] [Google Scholar]
  • 48. Gottlieb LK, Salem‐Schatz S: Anticoagulation in atrial fibrillation. Does efficacy in clinical trials translate into effectiveness in practice? Arch Intern Med 1994; 154: 1945–1953 [DOI] [PubMed] [Google Scholar]
  • 49. Gurwitz JH, Monette J, Rochon PA, Eckler MA, Avorn J: Atrial fibrillation and stroke prevention with warfarin in the long‐term care setting. Arch Intern Med 1997; 157: 978–984 [PubMed] [Google Scholar]
  • 50. Hendry A, Campbell AM, Campbell G, Macdonald JB, Williams BO: Antithrombotic therapy prescribed for patients with non‐rheumatic atrial fibrillation (letter). Scott Med J 1994; 39: 110 [DOI] [PubMed] [Google Scholar]
  • 51. Lip GY, Golding DJ, Nazir M, Beevers DG, Child DL, Fletcher RI: A survey of atrial fibrillation in general practice: The West Birmingham Atrial Fibrillation Project. Br J Gen Pract 1997; 47: 285–289 [PMC free article] [PubMed] [Google Scholar]
  • 52. Lip GY, Tean KN, Dunn FG: Treatment of atrial fibrillation in a district general hospital. Br Heart J 1994; 71: 92–95 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53. Munschauer FE, Priore RL, Hens M, Castilone A: Thromboembolism prophylaxis in chronic atrial fibrillation. Practice patterns in community and tertiary‐care hospitals. Stroke 1997; 28: 72–76 [DOI] [PubMed] [Google Scholar]
  • 54. O'Connell JE, Gray CS: Atrial fibrillation and stroke prevention in the community. Age Ageing 1996; 25: 307–309 [DOI] [PubMed] [Google Scholar]
  • 55. Stafford RS, Singer DE: National patterns of warfarin use in atrial fibrillation. Arch Intern Med 1996; 156: 2537–2541 [PubMed] [Google Scholar]
  • 56. Sudlow M, Thomson R, Thwaites B, Rodgers H, Kenny RA: Prevalence of atrial fibrillation and eligibility for anticoagulants in the community. Lancet 1998; 352: 1167–1171 [DOI] [PubMed] [Google Scholar]
  • 57. Whittle J, Wickenheiser L, Venditti LN: Is warfarin underused in the treatment of elderly persons with atrial fibrillation? Arch Intern Med 1997; 157: 441–445 [PubMed] [Google Scholar]
  • 58. Hohnloser SH, Kuck KH, Lilienthal J: Rhythm or rate control in atrial fibrillation‐Pharmacological Intervention in Atrial Fibrillation (PIAF): A randomised trial. Lancet 2000; 356: 1789–1794 [DOI] [PubMed] [Google Scholar]
  • 59. Laupacis A, Albers G, Dalen J, Dunn MI, Jacobson AK, Singer DE: Antithrombotic therapy in atrial fibrillation. Chest 1998; 114: 579S–589S [DOI] [PubMed] [Google Scholar]
  • 60. The SPAF III Writing Committee for the Stroke Prevention in Atrial Fibrillation Investigators : Patients with nonvalvular atrial fibrillation at low risk of stroke during treatment with aspirin: Stroke Prevention in Atrial Fibrillation III Study. J Am Med Assoc 1998; 279: 1273–1277 [PubMed] [Google Scholar]
  • 61. Pearce LA, Hart RG, Halperin JL: Assessment of three schemes for stratifying stroke risk in patients with nonvalvular atrial fibrillation. Am J Med 2000; 109: 45–51 [DOI] [PubMed] [Google Scholar]
  • 62. Hart RG, Benavente O, McBride R, Pearce LA: Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: A meta‐analysis. Ann Intern Med 1999; 131: 492–501 [DOI] [PubMed] [Google Scholar]
  • 63. Hart RG, Pearce LA, McBride R, Rothbart RM, Asinger RW: Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: Analysis of 2,012 participants in the SPAF I‐III clinical trials. The Stroke Prevention in Atrial Fibrillation (SPAF) Investigators. Stroke 1999; 30: 1223–1229 [DOI] [PubMed] [Google Scholar]

Articles from Clinical Cardiology are provided here courtesy of Wiley

RESOURCES